Slide 1: Financial Results Quarter Ended September 30, 2017
Financial Results Quarter Ended September 30, 2017
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : October, 30, 2017 Time : 05:00 pm IST Primary Number: +91 22 3938 1071 3940 3977 Available in - Ahmedabad, Bengaluru, Chandigarh, Chennai, Local Access Number: Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Pune, Lucknow. Accessible from all carriers. USA: 1 866 746 2133 U
Slide 4: Q2'FY18 Results Analysis
JUBHANT LIFESCIENCES Q2’FY18 Results Analysis
Slide 5: Income Statement – Q2'FY18
Income Statement – Q2’FY18 Particulars Q2'FY17 Q1'FY18 Q2'FY18 YoY Growth QoQ Growth (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 1,386 1,556 1,642 19% 5% Pharmaceuticals 766 815 860 12% 6% Life Science Ingredients 582 700 738 27% 5% Drug Discovery Solutions 38 41 44 16% 6% Total Expen
Slide 6: Corporate Action
Corporate Action Jubilant Pharma Limited (JPL), a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, successfully completed the acquisition of the US radiopharmacy business of Triad Isotopes, Inc. on September 1, 2017. Accordingly, the Q2/H1’FY18 revenues
Slide 7: Financial Highlights – Q2'FY18
Financial Highlights – Q2’FY18 • Consolidated revenue at Rs. 1,642 Crore; up 19% YoY • Pharmaceuticals revenue at Rs. 860 Crore, contributing 52% to the revenues, up 12% YoY • Life Science Ingredients revenue at Rs. 738 Crore, contributing 45% to the revenues, up 27% YoY • Drug Discovery Solutions r
Slide 8: Pharmaceuticals Segment Highlights – Q2'FY18
Pharmaceuticals Segment Highlights – Q2’FY18 • Revenues at Rs. 860 Crore, up 12% YoY • Specialty Pharmaceuticals - Injectables revenues of Rs. 531 Crore reported robust growth of 42% YoY and 13% QoQ; contributing 62% to Pharma segment sales and 32% to Company revenue • Generics revenues at Rs. 329 c
Slide 9: Pharmaceuticals Segment Highlights – Q2'FY18
Pharmaceuticals Segment Highlights – Q2’FY18 Region-wise Revenue (Rs Crs) Q2'FY17 Q1'FY18 Q2'FY18 Mix % YoY % QoQ % ROW International 706 778 831 97% 18% 7% 8.4% Europe & India Japan 3.4% North America 527 610 672 78% 27% 10% 10.0% Europe & Japan 93 102 86 10% -7% -15% ROW 86 65 72 8% -16% 10% North
Slide 10: Regulatory Status
Regulatory Status Regulatory Cadista Roorkee CMO / Allergy CMO JDI Montreal Nanjangud Agency USA India Spokane Montreal Canada India • All sites successfully inspected and fully compliant with USFDA Mar 2017 Mar 2017 Sep 2017 Dec 2016 Sep 2017 Oct 2015 regulations (USA) • Use the experience from Oct
Slide 11: LSI Segment Highlights – Q2'FY18
LSI Segment Highlights – Q2’FY18 Region-wise Revenue (Rs Crs) Q2'FY17 Q1'FY18 Q2'FY18 Mix % YoY % QoQ % ROW International 241 312 308 42% 28% -1% 16.5% Europe, North America and Japan 174 204 186 25% 7% -9% Europe, India ROW 67 108 122 16% 82% 12% North 58.3% America and India 341 388 430 58% 26% 11
Slide 12: Expenditure Analysis – Q2'FY18
Expenditure Analysis – Q2’FY18 YoY QoQ % of % of Expenses (Rs Crs) Q2'FY17 % of Sales Q1'FY18 Q2'FY18 Growth Growth Sales Sales % % Material Cost and Change in Inventory 410 30% 545 35% 556 34% 36% 2% Purchases of stock-in-trade 45 3% 38 2% 52 3% 15% 35% Employee benefits expense 301 22% 310 20% 369
Slide 13: Half-Yearly Results Analysis
Half-Yearly Results Analysis 12 12
Slide 14: Income Statement – H1'FY18
Income Statement – H1’FY18 Particulars H1'FY17 H1'FY18 YoY Growth (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 2,805 3,198 14% Pharmaceuticals 1,518 1,675 10% Life Science Ingredients 1,200 1,438 20% Drug Discovery Solutions 87 85 -3% Total Expenditure 2,097 2,554 22% Other Income 9 14
Slide 15: Financial Highlights – H1'FY18
Financial Highlights – H1’FY18 • Consolidated revenue at Rs. 3,198 Crore; up 14% YoY • Pharmaceuticals revenue at Rs. 1,675 Crore, up 10% YoY, contributing 52% to the revenues • LSI revenue at Rs. 1,438 Crore, up 20% YoY, contributing 45% to the revenues • Drug Discovery Solutions revenue at Rs. 85
Slide 16: Pharmaceuticals Segment Highlights – H1'FY18
Pharmaceuticals Segment Highlights – H1’FY18 • Revenues of Rs. 1,675 Crore, up 10% YoY • Specialty Pharmaceuticals - Injectables reported revenues of Rs. 1,000 Crore; robust growth of 28% YoY; contributing 60% to Pharma segment sales and 31% to Company revenue • Generics revenues at Rs. 675 crore, c
Slide 17: Pharmaceuticals Segment Highlights – H1'FY18
Pharmaceuticals Segment Highlights – H1’FY18 Geo-wise Revenue (Rs Crs) H1'FY17 H1'FY18 Mix % YoY % ROW, 8.2% International 1,411 1,608 96% 14% Europe & India, 4.0% USA & Canada 1,041 1,283 77% 23% Japan, Europe & Japan 198 188 11% -5% 11.2% ROW 172 137 8% -20% India 107 67 4% -38% USA & Canada, Inco
Slide 18: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Product pipeline as on September 30, 2017 Dosage (Orals) Injectables Region Total Filings Approval Pending Total Filings Approval Pending US 85 56 29 11 10 1 Canada 22 22 0 13 13 0 Europe 101 95 6 10 10 0 ROW 687 508 179 44 40 4 Total 895 681 214 78
Slide 19: Filings and Approvals
Filings and Approvals Dosage (Orals) Filed 85 ANDAs in the US i. 56 ANDAs have been approved and 29 ANDAs are pending approval ii. Filed 2 ANDAs in H1’FY18 Made 810 filings in ROW markets including Canada, Europe and Japan i. 625 filings have been approved and 185 filings are pending approval
Slide 20: LSI Segment Highlights – H1'FY18
LSI Segment Highlights – H1’FY18 Geo-wise Revenue (Rs Crs) H1'FY17 H1'FY18 Mix % YoY % China and International 537 620 43% 15% ROW, 16.0% Europe, North America and 383 390 27% 2% Japan Europe, India, China and ROW 154 230 16% 50% North 56.8% America and India 663 818 57% 23% Japan, 27.1% Income from
Slide 21: Drug Discovery Solutions Segment Highlights – H1'FY18
Drug Discovery Solutions Segment Highlights – H1’FY18 Geo-wise Revenue (Rs Crs) H1'FY17 H1'FY18 Mix % YoY % China and International 86 84 98% -3% ROW, 2% North America 62 63 74% 2% Europe and India, 2% Europe and Japan 23 19 22% -19% Japan, 22% North China and ROW 2 2 2% 26% America, India 1 1 2% 45
Slide 22: Expenditure Analysis – H1'FY18
Expenditure Analysis – H1’FY18 Expenses (Rs Crs) H1'FY17 % of Sales H1'FY18 % of Sales YoY Growth % Material Cost and Change in Inventory 838 30% 1,101 34% 31% Purchases of stock-in-trade 82 3% 90 3% 10% Employee benefits expense 597 21% 679 21% 14% Power and fuel expense 158 6% 193 6% 22% Others 42
Slide 23: Debt Profile
Debt Profile Particulars 31-Mar-17 30-Jun-17 30-Sep-17 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 19 19 19 Subsidiaries 407 387 392 Total 426 405 411 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,241 1,161 1,214 Subsidiaries 82 127 96 Total 1,323 1,288 1,310 Gross Debt 4,084 3,9
Slide 24: Outlook
Outlook Due to strong business performance in Specialty Pharmaceuticals – Injectables and better demand and pricing environment in LSI segment, we are confident of delivering significantly higher earnings in H2’FY18 as compared to H1’FY18 on account of the following: • Specialty Pharmaceuticals -
Slide 25: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 Ph: +91 22 6645 1209 E-mail: ravi.agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Kanika Bansal Jubilant Life Sciences Limited Perfect Relati